University of Wisconsin, Madison
The overall purpose of this research is to determine whether new macromolecular measures optimized for whole brain (gray matter and white matter) magnetic resonance imaging (MRI), predict neuro-cognitive impairment in multiple sclerosis (MS) patients.
MRI is a vital component of a MS work-up, providing noninvasive evidence of MS lesions, detecting active inflammatory lesions, and measuring brain atrophy to assess neurodegeneration. Recent years of MRI research have generated strong evidence of gray matter (GM) involvement in MS, resulting in the reclassification of MS as a whole-brain disease. Similar to white matter (WM), a primary target of MS pathology in GM is myelin, the protective sheath insulating the penetrating axons within GM and extending brain connectivity all the way to the neuronal bodies. This aim of this research is to exam…
Inclusion Criteria: * Clinically definite MS * Adult age 18 to 60 Exclusion Criteria: * Contraindication to MRI * Changes in MS therapy in the last 6 months * Less than 6 weeks after relapse or corticosteroid use * Currently taking medication that may affect cognition (e.g. donepezil, rivastigmine, adderall) * History of significant alcohol or drug abuse * Current or recent significant migraines * Confounding neurological or cognitive disorders or deficits (stroke, Parkinson's disease, Alzheimer's disease, epilepsy) * Sensory or physical impairments that might interfere significantly with c…
The MRI protocol will include conventional testing for MS lesion detection and functional MR imaging to localize associated neurocognitive domains in each subject.
A comprehensive battery of neuropsychological tests will be administered to assess memory, new learning, spatial processing and higher executive function.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.